Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis

NCT03558152 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03558152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03558152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2018
Completion date
December 15, 2021
Enrollment
195 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis